研究单位：[1]Beijing InnoCare Pharma Tech Co., Ltd.[2]Anqing Municipal Hospital,Anqing,Auhui,China,246003[3]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Auhui,China,233000[4]Beijing Tiantan Hospital, Capital Medical University,Beijing,China,100070[5]Beijing Tongren Hospital, Capital Medical University,Beijing,China,100730[6]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510055[7]Guangdong Provincial Hospital of Chinese Medicine,Guangzhou,Guangdong,China,510120[8]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[9]Henan Provincial Peoples Hospital,Zhengzhou,Henan,China,450003[10]Union Hospital Tongji Medical College Huazhong University of Science and Technology,Wuhan,Hubei,China,430000[11]Hunan Cancer Hospital,Changsha,Hunan,China,410000[12]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330006[13]Jiangxi Cancer Hospital,Nanchang,Jiangxi,China,330029[14]The Second Hospital of Dalian Medical University,Dalian,Liaoning,China,116023[15]The first Hospital of China Medical University,Shenyang,Liaoning,China,110002[16]The Affiliated Hospital Of Qingdao University,Qingdao,Shandong,China,266000[17]Yantai Yuhuangding Hospital,Yantai,Shandong,China,264099[18]Huashan Hospital, Fudan University,Shanghai,Shanghai,China,200040[19]The Second Affiliated Hospital of Xi''an Jiaotong University（Xibei Hospital）,Xi''an,Shanxi,China,710004[20]West China Hospital, Sichuan University,Chengdu,Sichuan,China,610041[21]The First Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003
研究目的：
Evaluate the Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Versus Placebo Plus R2 in Relapsed/Refractory Marginal Zone Lymphoma.
